Carbocyclic Ring Bonded Directly To The Carbon Of The Acid Group Patents (Class 562/622)
-
Patent number: 6511990Abstract: The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.Type: GrantFiled: August 24, 2000Date of Patent: January 28, 2003Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New YorkInventors: Ronald Breslow, Sandro Belvedere, Leland Gershell, Thomas A. Miller, Paul A. Marks, Victoria M. Richon, Richard A. Rifkind
-
Publication number: 20030013757Abstract: Compounds of formula I 1Type: ApplicationFiled: June 11, 2002Publication date: January 16, 2003Inventors: Ulrike Leser-Reiff, Tim Sattelkau, Gerd Zimmermann
-
Publication number: 20020188132Abstract: Compounds of the formula: 1Type: ApplicationFiled: December 4, 2000Publication date: December 12, 2002Inventors: Jeremy I. Levin, James M. Chen, Frances C. Nelson
-
Patent number: 6465468Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with matrix metalloproteinase, ADAM or ADAM-TS enzymes, a condition that is mediated by TNF &agr; or a condition involving a membrane-shedding event that is mediated by a metalloproteinase. Compounds of the invention are of formula I (B)2N—X—(CH2)m—W—(CR1R2)n—COY (I) wherein n=0 or 1; m=0 or 1; X is S(O)1-2; Y is OH or NHOH; W is aryl or heteroaryl; and the other groups are as defined herein.Type: GrantFiled: March 22, 2000Date of Patent: October 15, 2002Assignee: Darwin Discovery LimitedInventors: Andrew Douglas Baxter, David Alan Owen, Duncan Batty, Robert John Watson
-
Patent number: 6462042Abstract: Compounds having therapeutic utility are of formula (I) wherein B1, B2, R1 and R2 are each various sub-stituents, or R1 and R2 together form a ring.Type: GrantFiled: March 28, 2001Date of Patent: October 8, 2002Assignee: Darwin Discovery LimitedInventors: David Alan Owen, Andrew Douglas Baxter, Robert John Watson, John Gary Montana
-
Patent number: 6451859Abstract: Compounds having a structure according to the following formula: are effective in treating disorders such as bone disorders and glaucoma in a subject in need thereof.Type: GrantFiled: August 29, 2001Date of Patent: September 17, 2002Assignee: The Procter & Gamble CompanyInventors: Mitchell Anthony deLong, David Lindsey Soper, John August Wos, Biswanath De
-
Patent number: 6380219Abstract: A compound of the formula wherein n, X, R3, R4 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF.Type: GrantFiled: August 8, 2000Date of Patent: April 30, 2002Assignee: Pfizer IncInventors: Ralph P. Robinson, James P. Rizzi
-
Publication number: 20020006920Abstract: A compound of the formula 1Type: ApplicationFiled: July 18, 2001Publication date: January 17, 2002Inventors: Ralph Pelton Robinson, Kim Francis McClure
-
Patent number: 6326516Abstract: The invention discloses hydroxamide acids of the formula: which are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.Type: GrantFiled: January 27, 2000Date of Patent: December 4, 2001Assignee: American Cyanamid CompanyInventors: Jeremy I. Levin, James M. Chen, Arie Zask
-
Patent number: 6310084Abstract: The present invention relates to therapeutically active hydroxamic acid, N-formyl-N-hydroxyamino and carboxylic acid derivatives, their preparation, and pharmaceutical compositions containing them. These compounds are useful in the inhibition of metalloproteases, such as stromelysin, gelatinase, matrilysin, and collagenase. These compounds are useful in the treatment of mammals having disease-states alleviated by the inhibition of such matrix metalloproteases.Type: GrantFiled: February 11, 2000Date of Patent: October 30, 2001Assignee: British Biotech Pharmaceuticals LimitedInventors: Raymond Paul Beckett, Fionna Mitchell Martin, Richard Simon Todd
-
Patent number: 6291709Abstract: The subject invention involves processes for making hydroxamic acid compounds using a solid-support resin having an oxime moiety as the linking moiety of the resin, comprising the steps of (a) treating the resin with a carboxylic acid compound, such that it is attached to the resin by a condensation reaction between the oxime and carboxyl moieties; (b) optionally modifying the side chain; (c) cleaving a product from the resin by treating with O-tert-butyldimethylsilylhydroxylamine; (d) optionally modifying the side chain; and (e) optionally treating the resulting O-TBS-protected material with acid to produce an unprotected hydroxamic acid compound.Type: GrantFiled: July 7, 2000Date of Patent: September 18, 2001Assignee: The Procter & Gamble CompanyInventors: Adam Golebiowski, Sean Rees Klopfenstein
-
Patent number: 6288261Abstract: Compounds having the formula and pharmaceutically acceptable salts and prodrugs thereof are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.Type: GrantFiled: December 14, 1999Date of Patent: September 11, 2001Assignee: Abbott LaboratoriesInventors: David J. Augeri, David A. Betebenner, Richard Craig, Steven K. Davidsen, Stephen W. Fesik, Jamie R. Giesler-Stacey, Yan Guo, Philip J. Hajduk, Michael R. Michaelides, David G. Nettesheim
-
Patent number: 6277885Abstract: Hydroxamic acids having the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.Type: GrantFiled: January 27, 2000Date of Patent: August 21, 2001Assignee: American Cyanamid CompanyInventors: Jeremy I. Levin, James M. Chen
-
Patent number: 6187924Abstract: Compounds of formula (I) are useful as therapeutic agents, by virtue of having MMP and TNF inhibitory activity.Type: GrantFiled: November 12, 1998Date of Patent: February 13, 2001Assignee: Darwin Discovery, Ltd.Inventors: Andrew Douglas Baxter, David Alan Owen, John Gary Montana, Robert John Watson
-
Patent number: 6180818Abstract: A silver halide photographic material is disclosed, comprising a support having thereon at least one light-sensitive silver halide emulsion layer, wherein said silver halide photographic material contains a compound by formula (IA), or which contains at least one hydroxamic acid compound having a bicyclo ring as a partial structure and represented by formula (IB).Type: GrantFiled: November 3, 1999Date of Patent: January 30, 2001Assignee: Fuji Photo Film Co., Ltd.Inventors: Hisashi Mikoshiba, Hiroo Takizawa, Junichiro Hosokawa, Yoshio Ishii, Keiji Mihayashi, Masakazu Morigaki, Mamoru Sakurazawa
-
Patent number: 6156884Abstract: Reagents suitable for the modification of a bioactive species for the purpose of incorporating a bifunctional boronic compound complexing moiety for subsequent conjugation to a different (or the same) bioactive species having pendant phenylboronic acid moieties of General Formula 1, ##STR1## wherein group R is an electrophilic or nucleophilic moiety suitable for reaction of the putative bifunctional boronic compound complexing reagent with a bioactive species, wherein group R.sub.2 is selected from one of H and OH moieties, and wherein group R.sub.3 is selected from one of an alkyl and a methylene bearing an electronegative substituent. Group Z is a spacer selected from (CH.sub.2).sub.n and CH.sub.2 O(CH.sub.2 CH.sub.2 O).sub.n.sbsb.2, wherein n is an integer of from 1 to 5, and wherein n.sub.2 is an integer of from 1 to 4. Each of group Z.sub.2 and Z.sub.3 is a spacer selected from CH.sub.2 Ar, CH.sub.2 CONHCH.sub.2 Ar, CH.sub.2 CONH(CH.sub.2).sub.n.sbsb.3 CO--NHCH.sub.2 Ar, and (CH.sub.2).sub.n.sbsb.Type: GrantFiled: December 29, 1998Date of Patent: December 5, 2000Assignee: Prolinx, Inc.Inventors: Clarence N. Ahlem, Robert J. Kaiser, Kevin P. Lund, Mark L. Stolowitz
-
Patent number: 6127427Abstract: Compounds of general formula (I) ##STR1## wherein X ia a --CO.sub.2 H, --NH(OH)CHO or --CONHOH group; R.sub.1 is a cylcoalkyl, cycloalkenyl or non-aromatic heterocyclic ring containing up to 3 heteroatoms, any of which may be (i) substituted by one ore more substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, halo, cyano (--CN), --CO.sub.2 H, --CO.sub.2 R, --CONH.sub.2, --CONHR, --CON(R).sub.2, --OH, --OR, oxo-, --SH, --SR, --NHCOR, and --NHCO.sub.2 R wherein R is C.sub.1 -C.sub.6 alkyl or benzyl and/or (ii) fused to a cycloalky or heterocyclic ring; and R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined in specification are matrix metalloproteinase inhibitors.Type: GrantFiled: May 22, 1998Date of Patent: October 3, 2000Assignee: British Biotech Pharmaceuticals LimitedInventors: Fionna Mitchell Martin, Christopher Norman Lewis, Mark Whittaker
-
Patent number: 6114570Abstract: A silver halide photographic material is disclosed, comprising a support having thereon at least one light-sensitive silver halide emulsion layer, wherein said silver halide photographic material contains a compound by formula (IA), or which contains at least one hydroxamic acid compound having a bicyclo ring as a partial structure and represented by formula (IB).Type: GrantFiled: September 2, 1998Date of Patent: September 5, 2000Assignee: Fuji Photo Film Co., Ltd.Inventors: Hisashi Mikoshiba, Hiroo Takizawa, Junichiro Hosokawa, Yoshio Ishii, Keiji Mihayashi, Masakazu Morigaki, Mamoru Sakurazawa
-
Patent number: 5985911Abstract: C-terminal compounds of formula ##STR1## are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting compositions and a method of inhibiting matrix metalloproteinase in a mammal.Type: GrantFiled: December 17, 1997Date of Patent: November 16, 1999Assignee: Abbott LaboratoriesInventors: Steven K. Davidsen, Alan S. Florjancic, George S. Sheppard, Jamie R. Giesler, Lianhong Xu, Yan Guo, Michael L. Curtin, Michael R. Michaelides, Carol K. Wada, James H. Holms
-
Patent number: 5977408Abstract: The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha.Type: GrantFiled: October 6, 1997Date of Patent: November 2, 1999Assignee: American Cyanamid CompanyInventors: Jeremy Ian Levin, Arie Zask, Yansong Gu
-
Patent number: 5910609Abstract: Compounds of general Formula I: ##STR1## are presented which have collagenase inhibition activity and are useful in the management of disease involving tissue degradation and the promotion of wound healing. Representative diseases involving include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption disease and tumor invasion.Type: GrantFiled: April 5, 1995Date of Patent: June 8, 1999Assignee: British Biotech Pharmaceuticals LimitedInventors: Colin Campion, Alan Hornsby Davidson, Jonathan Philip Dickens, Michael John Crimmin
-
Patent number: 5883131Abstract: A compound of the formula ##STR1## wherein n, p, q, X, Y, Z and Ar are as defined herein, useful in the treatment of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis or other diseases characterized by matrix metalloprotenase activity, as well as AIDS, sepsis, septic shock or other diseases involving the production of TNF.Type: GrantFiled: July 9, 1997Date of Patent: March 16, 1999Assignee: Pfizer Inc.Inventors: Laurence E. Burgess, James P. Rizzi, David J. Rawson
-
Patent number: 5861436Abstract: The present invention relates to therapeutically active hydroxamic acid derivatives, to pharmaceutical compositions containing them, and to the therapeutic use of these compounds. In particular, the compounds are inhibitors of matrix metalloproteinases that are involved in tissue degradation, and in addition, are inhibitors of the release of tumor necrosis factor from cells.Type: GrantFiled: April 29, 1997Date of Patent: January 19, 1999Assignee: British Biotech Pharmaceuticals LimitedInventors: Raymond Paul Beckett, Mark Whittaker, Andrew Miller
-
Patent number: 5859010Abstract: The invention relates to novel compounds that potentiate zinc ion inhibition of the activity of factor VIIa or tissue factor--factor VIIa complex having the formula Ia and Ib and pharmaceutical salts thereof as well as pharmaceutical compositions comprising said novel compounds. The invention is further related to the use of said compositions for inhibiting clotting activity, tissue factor activity and factor VIIa activity.Type: GrantFiled: June 23, 1997Date of Patent: January 12, 1999Assignee: Novo Nordisk A/SInventors: Lars Christian Petersen, Ole Hvilsted Olsen, Stefan Lutz Richter, Palle Jakobsen
-
Patent number: 5837878Abstract: Boron compound complexing reagents, boron compound complexes, and methods of synthesizing these reagents and complexes are disclosed. These reagents and complexes include those shown in General Formula CIII, General Formula CIV, and General Formula CVI. In one embodiment, the reagents of General Formula CIII may be used to produce, after condensation with a bioactive species (BAS), the reagent of General Formula CIV. The reagent of General Formula CIV may be used to form a complex with a boron compound, such as a complex shown in General Formula CVI.Type: GrantFiled: August 5, 1996Date of Patent: November 17, 1998Assignee: Prolinx, Inc.Inventors: Mark L. Stolowitz, Robert J. Kaiser, Kevin P. Lund
-
Patent number: 5777164Abstract: The present invention discloses a method comprising the steps of;a) forming in an aqueous solution a hydroxamic acid from a hydroxylamine free base and anhydride having the formula (RCO).sub.2 O wherein R is H or a substituted or unsubstituted C.sub.2-6 alkyl, C.sub.2-6 alkenyl, C.sub.6-10 aryl, or C.sub.4-10 heteroaryl; andb) treating said hydroxamic acid with an alkylating agent in the presence of at least one proton scavenger under conditions sufficient to consume substantially all of said alkylating agent to form an O-substituted hydroxamate.The protection and alkylation are readily effected in water (with no alcohol co-solvent) without the need for phase-transfer catalysis and with little hydrolysis of the alkylating agent.Type: GrantFiled: April 14, 1997Date of Patent: July 7, 1998Assignee: Eastman Chemical CompanyInventor: Neil Warren Boaz
-
Patent number: 5744627Abstract: Boron compound complexing reagents, boron compound complexes, and methods of synthesizing these reagents and complexes are disclosed. These reagents and complexes include those shown in General Formula III, General Formula IV, and General Formula VI. In one embodiment, the reagents of General Formula III may be used to produce, after condensation with a bioactive species (BAS), the reagent of General Formula IV. The reagent of General Formula IV may be used to form a complex with a boron compound, such as a complex shown in General Formula VI.Type: GrantFiled: August 5, 1996Date of Patent: April 28, 1998Assignees: Prolinx, Inc., SystemixInventors: Mark L. Stowolitz, Robert J. Kaiser, Kevin P. Lund, Steven M. Torkelson
-
Patent number: 5668257Abstract: The present invention relates to a novel class of phenylboronic acid complexing reagents useful for the preparation of bioconjugates, and the method of making and using such reagents. In the present invention, in the place of prior art Avidin-Biotin and Digoxigenin-anti-Digoxigenin systems, phenylboronic acid complexing reagents are utilized in conjunction with phenylboronic acid reagents (many of which are known in the prior art) to facilitate chemical conjugation without the use of intermediary biological macromolecules. Reagents suitable for the modification of a bioactive species for the purpose of incorporating a phenylboronic acid complexing moiety for subsequent conjugation to a different bioactive species having pendant phenylboronic acid moieties are of General Formula I or General Formula II. ##STR1## wherein group X is selected from either H, OH, NH.sub.2, NHCH.sub.3, NHOH and NHOCH.sub.Type: GrantFiled: June 7, 1995Date of Patent: September 16, 1997Assignee: Prolinx, Inc.Inventor: Mark L. Stolowitz
-
Patent number: 5656619Abstract: Abstract of the Disclosure: Diphenylheteroalkyl derivatives of the formula I ##STR1## where A and R.sup.1 -R.sup.6 have the meanings specified in the description, and the preparation thereof are described.The substances are suitable for controlling diseases and as cosmetic agents.Type: GrantFiled: June 6, 1995Date of Patent: August 12, 1997Assignee: BASF AktiengesellschaftInventors: Bernd Janssen, Hans-Heiner Wuest
-
Patent number: 5608108Abstract: The invention provides compounds, several of which belong to a class having two or more nonpolar components connected by a polar group and having polar groups on the termini of the compound.The invention also concents a method of selectively inducing termini differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effect to selectively induce terminal differentiation.Moreover, the invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells, thereby inhibiting their proliferation and suppressing oncogenicity.Type: GrantFiled: April 17, 1995Date of Patent: March 4, 1997Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia Univeristy in the City of New YorkInventors: Paul A. Marks, Richard A. Rifkind, Ronald Breslow, Branko Jursic
-
Patent number: 5594106Abstract: Compounds and methods are disclosed that are useful in inhibiting the TNF-.alpha. converting enzyme (TACE) responsible for cleavage of TNF-.alpha. precursor to provide biologically active TNF-.alpha.. The compounds employed in the invention are peptidyl derivatives having active groups capable of inhibiting TACE such as, hydroxamates, thiols, phosphoryls and carboxyls.Type: GrantFiled: August 18, 1994Date of Patent: January 14, 1997Assignee: Immunex CorporationInventors: Roy A. Black, Jeffrey N. Fitzner, Paul R. Sleath
-
Patent number: 5594151Abstract: The present invention relates to a novel class of phenylboronic acid complexing reagents useful for the preparation of bioconjugates, and the method of making and using such reagents. In the present invention, in the place of prior art Avidin-Biotin and Digoxigenin-anti-Digoxigenin systems, phenylboronic acid complexing reagents are utilized in conjunction with phenylboronic acid reagents (many of which are known in the prior art) to facilitate chemical conjugation without the use of intermediary biological macromolecules. Reagents suitable for the modification of a bioactive species for the purpose of incorporating a phenylboronic acid complexing moiety for subsequent conjugation to a different bioactive species having pendant phenylboronic acid moleties are of General Formula I or General Formula II. ##STR1## wherein group X is selected from either H, OH, NH.sub.2, NHCH.sub.3, NHOH and NHOCH.sub.Type: GrantFiled: January 28, 1994Date of Patent: January 14, 1997Assignee: Prolinx, Inc.Inventor: Mark L. Stolowitz
-
Patent number: 5487842Abstract: N-ethyl alkanohydroxamic acids, where said alkyl group is a straight chain alkyl group of 8 to 10 carbon atoms, or a branched alkyl group of 8 to 25 carbon atoms, provided said alkyl group is not cyclic, useful as metal chelants for use in organic solvent extractant solutions such as kerosene to extract metals from aqueous solutions by forming complexes of the extracted metal with the N-ethyl hydroxamic acid. Metals can be stripped from complexes of N-ethyl hydroxamic acids at higher concentrations into lower strength acid stripping agents. The N-ethyl hydroxamic acid-containing organic solvent extraction solutions exhibit rapid phase separation from aqueous solutions, good hydrolytic stability and resistance to forming emulsions.Type: GrantFiled: July 11, 1994Date of Patent: January 30, 1996Assignee: Met-Tech Systems LimitedInventor: Bruce F. Monzyk
-
Patent number: 5430157Abstract: A series of tetrahydrophenanthrenes are useful as inhibitors of 5.alpha.-reductase.Type: GrantFiled: December 13, 1993Date of Patent: July 4, 1995Assignee: Eli Lilly and CompanyInventor: James E. Audia
-
Patent number: 5407951Abstract: The present invention provides sulphonamides of the general formula: ##STR1## wherein R.sup.1 and R.sup.2, which can be the same or different, are hydrogen or halogen atoms or C.sub.1 -C.sub.6 -alkyl, trifluoro-methyl, cyano, carboxyl, alkoxycarbonyl, aminocarbonyl, N-alkylaminocarbonyl or N,N-dialkylaminocarbonyl radicals or, when R.sup.1 and R.sup.2 are alkyl radicals ortho to one another, R.sup.1 and R.sup.2 together with the carbon atoms to which they are attached, form a saturated or unsaturated C.sub.5-C.sub.7 -alkylene ring, R.sup.3 is a hydrogen atom, an alkyl radical containing up to 6 carbon atoms, an acyl radical, a phenylalkyl or phenylalkenyl radical, the phenyl moiety of which can be substituted by halogen, alkyl or trifluoromethyl, C is a --(CH.sub.2).sub.m --radical, in which m is 0, 1, 2 or 3, or a branched C.sub.2 -C.sub.5 -alkylene radical, whereby a methylene radical --CH.sub.Type: GrantFiled: June 30, 1992Date of Patent: April 18, 1995Assignee: Boehringer Mannheim GmbHInventors: Ernst-Christian Witte, Karlheinz Stegmeier, Liesel Doerge
-
Patent number: 5328626Abstract: N-ethyl alkanohydroxamic acids, where said alkyl group is a straight chain alkyl group of 8 to 10 carbon atoms, or a branched alkyl group of 8 to 18 carbon atoms, provided said alkyl group is not cyclic, useful as metal chelants for use in organic solvent extractant solutions such as kerosene to extract metals from aqueous solutions by forming complexes of the extracted metal with the N-ethyl hydroxamic acid. Metals can be stripped from complexes of N-ethyl hydroxamic acids at higher concentrations into lower strength acid stripping agents. The N-ethyl hydroxamic acid-containing organic solvent extraction solutions exhibit rapid phase separation from aqueous solutions, good hydrolytic stability and resistance to forming emulsions.Type: GrantFiled: May 29, 1992Date of Patent: July 12, 1994Assignee: Met-Tech Systems, Ltd.Inventor: Bruce F. Monzyk
-
Patent number: 5304549Abstract: Compounds of the formula ##STR1## wherein A is the group ##STR2## R.sup.1 is hydrogen, amino, protected amino, acylamino or lower alkyl optionally substituted by aryl, hydroxy, protected hydroxy, amino, protected amino, acylamino, maleimido, succinimido, naphthalimido, 2,3-dihydro-1,3-dioxo-1H-benz[d,e]isoquinol-2-yl, carboxy, protected carboxy, carbamoyl, mono(lower alkyl)carbamoyl, di(lower alkyl)carbamoyl, di(lower alkyl)amino, carboxy-lower alkanoylamino, pyrrolidino or morpholino; R.sup.2 is hydrogen or lower alkyl optionally substituted by aryl, amino, protected amino, di(lower alkyl)- amino, guanidino, carboxyl, protected carboxyl, carbamoyl, mono(lower alkyl) carbamoyl, di(lower alkyl)carbamoyl, di(lower alkoxy)phosphinyl, dihydroxyphosphinyl, pyrrolidino, piperidino or morpholino; R.sup.3 is hydrogen or lower alkyl optionally substituted by hydroxy, protected hydroxy, amino or protected amino; R.sup.4 is hydrogen, hydroxy, lower alkoxy or benzyloxy; and R.sup.Type: GrantFiled: January 21, 1992Date of Patent: April 19, 1994Assignee: Hoffmann-La Roche Inc.Inventors: Michael J. Broadhurst, Paul A. Brown, William H. Johnson, Geoffrey Lawton
-
Patent number: 5245071Abstract: Compounds of the formula ##STR1## wherein A is a hydrogen atom, a halogen atom, a methyl group, or a methoxy group;B is a hydrogen atom, a halogen atom, a methyl group, or a methoxy group, with the proviso that A and B ar not both a hydrogen atom;X and Y each are an oxygen atom or a sulfur atom;R is a hydrogen atom, an alkyl group, a hydroxy group, an alkoxy group, an alkoxymethyl group, an acyl group, or an alkoxycarbonyl group;R.sub.1 is a hydrogen atom, an alkyl group, a halogen substituted alkyl group, an alkoxy substituted alkyl group, an alkylthio substituted alkyl group, a cyano substituted alkyl group, a 1-cycloalkenyl group, a benzyl group, a halogen substituted benzyl group, a hydroxy group, an alkoxy group, an acyl group, an alkoxycarbonyl group, an alkoxythiocarbonyl group, an alkylsulfonyl group, or a phenylsulfonyl group, while furthermore R and R.sub.1 together with the group ##STR2## indicated in the above formula may form a ring system; and R.sub.Type: GrantFiled: June 3, 1992Date of Patent: September 14, 1993Assignee: Duphar International Research B.V.Inventors: Kobus Wellinga, Rudolf Mulder
-
Patent number: 5240958Abstract: Compounds of general formula I: ##STR1## wherein: R.sup.1 represents a C.sub.1 -C.sub.6 alkyl, phenyl, thiophenyl, substituted phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, heterocyclyl, (C.sub.1 -C.sub.6)alkylcarbonyl phenacyl or substituted phenacyl group; or, when n=O, R.sup.1 represents SR.sup.x, wherein R.sup.x represents a group: ##STR2## R.sup.2 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl (C.sub.1 -C.sub.6) alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl or cycloalkenyl(C.sub.1 -C.sub.6)alkyl group;R.sup.3 represents an amino acid residue with R or S stereochemistry or a C.sub.1 -C.sub.6 alkyl, benzyl, (C.sub.1 -C.sub.6 alkoxy)benzyl or benzyloxy(C.sub.1 -C.sub.6 alkyl) group;R.sup.4 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group;R.sup.5 represents a hydrogen atom or a methyl group;n is an integer having the value 0, 1 or 2; andA represents a C.sub.1 -C.sub.6 hydrocarbon chain, optionaly substituted with one or more C.sub.1 -C.sub.Type: GrantFiled: July 8, 1991Date of Patent: August 31, 1993Assignee: British Bio-Technology LimitedInventors: Colin Campion, Alan H. Davidson, Jonathan P. Dickens, Michael J. Crimmin
-
Patent number: 5187192Abstract: Compounds of the structure ##STR1## where M is a pharmaceutically acceptable cation or a metabolically cleavable group, R is alkyl, cycloalkyl or --NR.sup.1 R.sup.2, where R.sup.1 and R.sup.2 are hydrogen, alkyl, cycloalkyl or alkanoyl, and A is optionally substituted alkyl, cycloalkyl, carbocyclic aryl, benzo[b]furyl, thienyl, or benzo[b]thienyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.Type: GrantFiled: March 13, 1992Date of Patent: February 16, 1993Assignee: Abbott LaboratoriesInventors: Dee W. Brooks, Karen E. Rodriques
-
Patent number: 5174917Abstract: N-ethyl hydroxamic acids, preferably containing at least 10 carbon atoms, useful as metal chelants for use in organic solvent extractant solutions such as kerosene to extract metals from aqueous solutions by forming complexes of the extracted metal with the N-ethyl hydroxamic acid. Metals can be stripped from complexes of N-ethyl hydroxamic acids at higher concentrations into lower strength acid stripping agents. The N-ethyl hydroxamic acid-containing organic solvent extraction solutions exhibit rapid phase separation from aqueous solutions and resistance to forming emulsions.Type: GrantFiled: July 19, 1991Date of Patent: December 29, 1992Assignee: Monsanto CompanyInventor: Bruce F. Monzyk
-
Patent number: 5175191Abstract: The invention provides compounds, several of which belong to a class having two or more nonpolar components connected by a polar group and having polar groups on the termini of the compound.The invention also concerns a method of selectively inducing termini differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effect to selectively induce terminal differentiation.Moreover, the invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells, thereby inhibiting their proliferation and suppressing oncogenicity.Type: GrantFiled: May 14, 1990Date of Patent: December 29, 1992Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University Institute for Cancer Research in the City of New YorkInventors: Paul A. Marks, Richard A. Rifkind, Ronald Breslow, Branko Jursic
-
Patent number: 5155110Abstract: The present invention is novel selected hydroxamic acid derivatives of fenamic acids having 5-lipoxygenase and cyclooxygenase inhibiting properties, pharmaceutical compositions for treating conditions advantageously affected by the inhibition and methods for treating these conditions in mammals, including humans suffering therefor.Type: GrantFiled: September 26, 1988Date of Patent: October 13, 1992Assignee: Warner-Lambert CompanyInventors: David T. Connor, Daniel L. Flynn
-
Patent number: 5128479Abstract: Oxidized diphenylheteroalkanes of the formula I ##STR1## where R.sup.1 to R.sup.6 and A have the meanings specified in the description, and the preparation thereof are described. The substances are suitable for controlling diseases and as cosmetic agents.Type: GrantFiled: January 29, 1990Date of Patent: July 7, 1992Assignee: BASF AktiengesellschaftInventors: Bernd Janssen, Hans-Heiner Wuest
-
Patent number: 5117054Abstract: The invention provides a process for preparing 1,5-diaryl pyrazole anti-inflammatory agents. A 6-aryl-4,6-dioxohexanoic acid is treated with acetic anhydride or acetyl chloride to produce an enol lactone, which is added to methylhydroxylamine to generate the dione hydroxamic acid. This dione hydroxamic acid is then treated with 4-methoxyphenylhydrazine hydrochloride to yield the 1,5-diaryl pyrazole. Novel intermediate compounds in the synthetic pathway are also disclosed.Type: GrantFiled: September 26, 1991Date of Patent: May 26, 1992Assignee: Ortho Pharmaceutical CorporationInventor: William V. Murray
-
Patent number: 5101066Abstract: There are provided novel compounds useful as selective extractants of metal values from aqueous systems comprising a plurality of such ionic species. There is further provided a process for the production of the novel compounds. The invention also relates to a process of selective metal extraction by means of the novel compounds of the invention.Type: GrantFiled: November 24, 1989Date of Patent: March 31, 1992Assignee: Yeda Research and Development Co. Ltd.Inventors: Abraham Shanzer, Jacqueline Libman, Shneior Lifson
-
Patent number: 5093356Abstract: Compounds having the formula I: ##STR1## are inhibitors of the 5-lipoxygenase enzyme. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.Type: GrantFiled: January 16, 1990Date of Patent: March 3, 1992Assignee: Merck Frosst Canada, Inc.Inventors: Yves Girard, Pierre Hamel, Daniel Delorme
-
Patent number: 5041648Abstract: .beta.-ionone pheylhydrazones of the formula I ##STR1## where R has the meaning indicated in the description, and the preparation thereof are described. The substances are suitable or controlling diseases and as cosmetic agents.Type: GrantFiled: January 22, 1990Date of Patent: August 20, 1991Assignee: BASF AktiengesellschaftInventors: Bernd Janssen, Hans-Heiner Wuest
-
Patent number: 5011854Abstract: A hydroxamic acid compound represented by the general formula (I) or a salt thereof; ##STR1## wherein R.sup.1 represents a hydrogen atom, or a substituted or unsubstituted alkanoyl group, R.sup.2 represents an unsubstituted alkanoyl, substituted lower alkanoyl or substituted lower alkyl group, and m represents an integer of 3 to 7, which are useful for the prevention and/or treatment of diseases caused by lipoxygenase-mediated metablites.Type: GrantFiled: December 7, 1989Date of Patent: April 30, 1991Assignee: Kyowa Hakko Kogyo Co. Ltd.Inventors: Mitsuru Takahashi, Shigeto Kitamura, Hiroshi Kase, Masaji Kasai, Isao Kawamoto, Takao Iida, Hiroshi Sano, Hiromitsu Saito, Koji Yamada, Chikara Murakata
-
Patent number: 4996358Abstract: Compounds of the formula ##STR1## wherein A is a group of the formula HN(OH)--CO-- or HCO--N(OH)--; R.sup.1 is a C.sub.2 -C.sub.5 -alkyl; R.sup.2 is the characterizing group of a natural .alpha.-amino acid in which any functional group present may be protected, any amino group present may be acylated and any carboxyl group present may be amidated, with the proviso that R.sup.2 is not hydrogen or methyl; R.sup.3 is hydrogen, amino, hydroxy, mercapto, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.6 -alkylamino, C.sub.1 -C.sub.6 -alkylthio or aryl-(C.sub.1 -C.sub.6 -alkyl), or amino-(C.sub.1 -C.sub.6 -alkyl), hydroxy-(C.sub.1 -C.sub.6 -alkyl), mercapto-(C.sub.1 -C.sub.6 -alkyl) or carboxy-(C.sub.1 -C.sub.6 -alkyl) in which the amino, hydroxy, mercapto or carboxyl group may be protected, the amino group may be acylated or the carboxyl group may be amidated; R.sup.4 is hydrogen or methyl; R.sup.5 is hydrogen or a C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy-C.sub.1 -C.sub.6 -alkyl, di(C.Type: GrantFiled: April 11, 1989Date of Patent: February 26, 1991Assignee: Hoffmann-La Roche Inc.Inventors: Balraj K. Handa, William H. Johnson, Peter J. Machin